FDA grants fast track status to Artiva’s AlloNK for lupus nephritis

The cell therapy manufacturing platform of Artiva can produce thousands of doses of AlloNK cells from a single umbilical cord blood unit. Credit: Trust “Tru” Katsande on Unsplash.